Skip to main content

Barwon Health / Research

(03) 4215 0000

Cancer Services Trials Unit - A/Prof Philip Campbell


I am a medical graduate from the University of Sheffield in the UK. Prior to my appointment at University Hospital Geelong in 2002, I completed adult physician training in internal medicine at Westmead Hospital in Sydney, before undertaking clinical and laboratory haematology training at Royal Prince Alfred Hospital in Sydney and University College Hospital, London. I established Victoria’s only regional autologous stem cell transplant service in 2003 in collaboration with the Royal Melbourne Hospital Bone Marrow Transplant Service. I am active member of both the Haematology Society of Australia and New Zealand and the Australasian Leukaemia and Lymphoma Group.

I currently hold the position of Director Cancer Services, University Hospital, Barwon Health

Research Focus

My current clinical research interests include multicentre, collaborative national and international trials in chronic lymphocytic leukaemia and multiple myeloma.Philip Campbell about me


Feature Publications

  • Kenneth F Bradstock, Emma Link, Juliana Di Iulio, Jeff Szer, Andrew Grigg, Andrew Roberts, Warwick Benson, Mark Hertzberg, Arno Enno, Sandra Deveridge, Phillip Rowlings, Paula Marlton, Anthony Mills, Devinder Gill,  Anthony Schwarer,  Ian D Lewis, Peter Bardy,  James D’Rozario, Luke Coyle, Gavin Cull, Phillip Campbell,  Andrew Wei, Michael Leahy, Uwe Hahn, Paul Cannell, Campbell Tiley, Ray Lowenthal, John Moore, Kimberley Cartwright, Ilona Cunningham, John Taper, Lynda Campbell, John F Seymour; Australasian Leukaemia and Lymphoma Group (ALLG). Idarubicin dose escalation during consolidation therapy for adult acute myeloid leukemia. J Clin Oncol 2017;35(15):1678–85
  • Chong Chyn Chua, Hui Yin Lim, Khai Li Chai, Jeremy Ong, Shirlene Sim, Colin Wood, Michael Dickinson, Philip Campbell, Jennifer Hempton, Hayley King, Claire Dowsing, Krystal Bergin, Sharon Muir, Simon Gibbs, Andrew Grigg. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. Bone Marrow Transplantation 2018.
  • Horvath NSpencer AKenealy MJoshua DCampbell PJLee JJHou JQiu LKalff AKhong TLondhe ASiggins Svan Kooten Losio MEisbacher MPrince HM. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leuk Lymphoma 2019 Feb 19. 1-12  doi: 10.1080/10428194.2019.1579322 . [Epub ahead of print]
  • Paolo Ghia, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Simkovic, Polina Kaplan, Iryna Kraychok, Arpad Illes, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric Avery, Jae Hoon Lee, Wei Liang, Priti Patel, Cheng Quah, and Wojciech Jurczak. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    J Clin Oncol: 2020. Published online May 27, 2020.
  • ALCYONE Update Manuscript, titled “Overall survival with daratumumab, bortezomib, melphalan and prednisone in newly diagnosed multiple myeloma: results of the phase 3 ALCYONE study” has been accepted for publication by The Lancet. Dec 2019

How you can help

Participate in a Clinical Trial

To find out about Clinical Trials currently underway at Barwon Health, click here. To learn more about the Adrian Costa Clinical Trials Centre, click here.


Research requires ongoing investment and there are several ways to support our work. You can make a donation today and contribute to an item on our research group’s wish list, consider a bequest in your will, or establish a lasting legacy fund in your name. No matter what size, your philanthropic support will deliver an immediate impact to this important work. To donate now or for more information, please contact the Barwon Health Foundation.

Last Modified: Monday, 26 September 2022

Philip Campbell

A/Prof Philip Campbell


Director of Cancer Services

Head of Clinical Haematology Barwon Health

Clinical Associate Professor

Deakin University School of Medicine

Principal Investigator, CSTU

[email protected]

Phone: (03) 4215 2778